Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that over 90% of patients undergoing paclitaxel and platinum chemotherapy for certain gynecological cancers experienced significant, yet reversible, alopecia by the end of treatment.

The robotic system for hair restoration surgery works well, giving similar results to manual techniques after 9 months.

This study found that men with early-onset male pattern alopecia did not significantly differ from healthy individuals in cardiovascular and metabolic measures, but hsCRP and galectin-3 were linked to cardiovascular risk factors in those with the condition.

This study found that FUE megasession with a specific surgical design is an effective and satisfactory treatment for Asian patients with high-grade male androgenetic alopecia, achieving natural hair density and high patient and doctor satisfaction, with minimal side effects.

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

Bicalutamide mesotherapy improved hair density in women with hair loss and was well received.

This study found that combining basic fibroblast growth factor with minoxidil improved hair treatment efficiency and patient satisfaction compared to minoxidil alone for early-stage androgenetic alopecia in men.

Scalp cooling significantly reduces hair loss in chemotherapy patients.

Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.

The meeting showcased rare skin disease cases, highlighting the need for accurate diagnosis and treatment.

In this study, safusidenib erbumine was evaluated for its efficacy and safety in patients with untreated IDH1-mutated WHO grade 2 gliomas, achieving a 44.4% objective response rate and 87.9% 24-month event-free probability, but with some mild to moderate adverse effects.

This study discusses patterns of androgenetic alopecia in Indian men but reports no new clinical findings.

The document explains how hair loss patterns in men and women, known as Androgenetic alopecia, are classified using the Hamilton-Norwood system for men and the Ludwig grade system for women.

This article reviews the classification systems for androgenetic alopecia and reports no new research findings.

This workshop review from the Australian Hair and Wool Research Society discusses findings in cutaneous biology and endocrinology but presents no new research results.

In this study, PRP treatment improved hair loss in 40 female patients with female pattern alopecia, with most progressing to better grades of hair coverage after 6 months, while only minor pain was occasionally reported as an adverse effect.

This study found that using a combination of 10% topical minoxidil, oral finasteride, and microneedling for six months effectively improved male pattern baldness with moderate to excellent responses and high patient satisfaction, without major side effects among the 25 participants.

This study reported that multiple factors including genetics and psychological influences are related to androgenetic alopecia, and finasteride showed a 77.8% response rate after three months of treatment.

This article discusses Propecia in dermatology but provides no new research findings.

In this study, the combination of scalp cooling therapy and a scalp lotion containing DHL-HisZnNa demonstrated a 91.3% hair recovery rate among breast cancer patients undergoing certain chemotherapy regimens, with no serious adverse events reported.

This study reports that a single injection of stromal vascular fraction (SVF) cells into the scalp of patients with androgenetic alopecia significantly increased hair density and thickness within 3 to 6 months, with no observed side effects.

This study found that scalp hypothermia effectively prevented chemotherapy-induced alopecia in 57.3% of breast cancer patients, with side effects such as a feeling of cold and slight headaches reported in 16% of cases.

This study found that concurrent chemotherapy with radiotherapy may increase the risk of grade 2 persistent radiation-induced alopecia, while topical minoxidil showed potential benefits, though more research is needed on its efficacy.

This study found that platelet-rich plasma was not effective in treating androgenetic alopecia in men with grade 4–6 hair loss.

This study found that combining the PAXMAN scalp cooling system with HairRepro MEDI α lotion led to a 50% success rate in reducing chemotherapy-induced alopecia and achieved complete hair regrowth by 3 months in Japanese breast cancer patients, suggesting enhanced efficacy over scalp cooling alone.

This study found that administering 5 mg of oral minoxidil daily for 24 weeks led to a 20.3% increase in hair density among men with androgenetic alopecia, although side effects like hypertrichosis and hypotension were observed.

This study found an association between vertex baldness and prostate cancer, especially for high-grade tumors in men aged 60-69, suggesting a possible shared androgen pathway.

This study observed that topical dinitrochlorobenzene was significantly more effective than topical betamethasone in treating patients with alopecia areata, with 53.3% achieving excellent hair regrowth compared to 13.3% using betamethasone.

This study reported that newly established dermoscopic diagnostic and grading criteria for androgenetic alopecia are highly accurate, with sensitivity and specificity at 98.3% and 96.7%, respectively.

In this study, injecting two different concentrations of botulinum toxin A was found to be safe and effective for treating androgenetic alopecia in Egyptian men and women, with improvements in hair grade and vellus hair density observed over six months.